411 related articles for article (PubMed ID: 34359938)
1. Transthyretin: From Structural Stability to Osteoarticular and Cardiovascular Diseases.
Wieczorek E; Ożyhar A
Cells; 2021 Jul; 10(7):. PubMed ID: 34359938
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
3. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Zhao L; Buxbaum JN; Reixach N
Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
[TBL] [Abstract][Full Text] [Related]
4. Deep blue autofluorescence reflects the oxidation state of human transthyretin.
Wieczorek E; Wygralak Z; Kędracka-Krok S; Bezara P; Bystranowska D; Dobryszycki P; Ożyhar A
Redox Biol; 2022 Oct; 56():102434. PubMed ID: 35987087
[TBL] [Abstract][Full Text] [Related]
5. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
6. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.
Gustavsson A; Jahr H; Tobiassen R; Jacobson DR; Sletten K; Westermark P
Lab Invest; 1995 Nov; 73(5):703-8. PubMed ID: 7474944
[TBL] [Abstract][Full Text] [Related]
7. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
8. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
[TBL] [Abstract][Full Text] [Related]
9. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes.
Sartiani L; Bucciantini M; Spinelli V; Leri M; Natalello A; Nosi D; Maria Doglia S; Relini A; Penco A; Giorgetti S; Gerace E; Mannaioni G; Bellotti V; Rigacci S; Cerbai E; Stefani M
Biophys J; 2016 Nov; 111(9):2024-2038. PubMed ID: 27806283
[TBL] [Abstract][Full Text] [Related]
11. Destabilisation of the structure of transthyretin is driven by Ca
Wieczorek E; Kędracka-Krok S; Bystranowska D; Ptak M; Wiak K; Wygralak Z; Jankowska U; Ożyhar A
Int J Biol Macromol; 2021 Jan; 166():409-423. PubMed ID: 33129902
[TBL] [Abstract][Full Text] [Related]
12. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
13. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
[TBL] [Abstract][Full Text] [Related]
14. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
15. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
[TBL] [Abstract][Full Text] [Related]
16. Cooperative stabilization of transthyretin by clusterin and diflunisal.
Greene MJ; Klimtchuk ES; Seldin DC; Berk JL; Connors LH
Biochemistry; 2015 Jan; 54(2):268-78. PubMed ID: 25478940
[TBL] [Abstract][Full Text] [Related]
17. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
[TBL] [Abstract][Full Text] [Related]
18. Stability and crystal structures of His88 mutant human transthyretins.
Yokoyama T; Hanawa Y; Obita T; Mizuguchi M
FEBS Lett; 2017 Jul; 591(13):1862-1871. PubMed ID: 28563699
[TBL] [Abstract][Full Text] [Related]
19. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands.
Arsequell G; Planas A
Curr Med Chem; 2012; 19(15):2343-55. PubMed ID: 22471983
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.
Peterson SA; Klabunde T; Lashuel HA; Purkey H; Sacchettini JC; Kelly JW
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):12956-60. PubMed ID: 9789022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]